Blog

Efinopegdutide (MK‑6024): Dual GLP‑1/Glucagon Peptide for Metabolic Liver Disease

Efinopegdutide (MK‑6024) is a dual GLP‑1/glucagon receptor agonist under investigation for treating metabolic-associated fatty liver disease (MAFLD) and related metabolic disorders. Developed by Merck, this synthetic, PEGylated peptide is engineered to improve liver fat reduction, glucose control, and cardiometabolic health. While GLP‑1 agonists like semaglutide and liraglutide have transformed the treatment of obesity and type 2 […]

Blog

Peptide Delivery Methods: Injections vs Oral vs Nanoparticles Explained

Peptides are powerful therapeutic and performance-enhancing agents — but their effectiveness depends heavily on how they’re delivered. While traditional injections remain the gold standard for bioavailability, emerging technologies like oral delivery systems, transdermal patches, and nanoparticles are revolutionizing the way peptides enter the body. In this guide, we’ll explore how different peptide delivery methods affect: → […]